PancragenvsXenin-25

Molecular Formula

C₂₆H₃₆N₆O₉

Molecular Weight

576.6 g/mol

Half-Life

Short plasma half-life typical of tetrapeptides; biological effects persist for weeks through epigenetic modifications to pancreatic gene expression (primate studies showed partial effects 3 weeks post-treatment); metabolized to constituent amino acids

Bioavailability

Demonstrated efficacy with both oral (Pankragen-Forte capsules) and intramuscular routes; penetrates cell membranes and nuclear membranes to reach DNA promoter regions; oral bioavailability sufficient for clinical effects at 500 mcg doses

CAS Number

Not definitively assigned

Molecular Formula

C₁₃₉H₂₂₄N₃₈O₃₂S

Molecular Weight

2971.6 g/mol

Half-Life

10-15 minutes (IV administration, subject to variation)

Bioavailability

IV: ~100%; Subcutaneous: Research-dependent; Oral: Limited due to peptide nature (active research)

CAS Number

Not available

Common

• Injection site reaction
• Mild fatigue
• Mild headache
• Minor digestive changes

Uncommon

• Mild hypoglycemia

Serious

• No documented serious adverse effects

Common

• Gastrointestinal Discomfort
• Nausea
• Headache

Uncommon

• Injection Site Reactions
• Mild Fatigue

Serious

• Hypoglycemia Risk

Evidence Level

Limited human trials

FDA Status

Research compound

Safety Overview

Pancragen shows favorable safety profile in preclinical toxicology studies with no serious adverse events at therapeutic doses. As a multi-peptide complex derived from pancreatic tissue, potential allergenicity risk exists in porcine-sensitive individuals. Gastrointestinal tolerance is excellent when taken orally. Limited human clinical data; primarily used in clinical practice in Central/Eastern Europe with reported safety in observational studies.

Contraindications

• xKnown hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid, aspartic acid, tryptophan)
• xPregnancy and breastfeeding — insufficient reproductive safety data
• xActive hypoglycemia or insulin-secreting tumors (insulinoma) — Pancragen's beta-cell stimulating effects may exacerbate hypoglycemia
• xConcurrent use of sulfonylureas without medical supervision — potential for additive hypoglycemic effects

Evidence Level

Moderate human trials (Phase 1-2)

FDA Status

Research compound

Safety Overview

Xenin-25 is a 25-amino acid natural gut peptide discovered in 1992 with moderate evidence from Phase 1-2 human clinical trials. The peptide has been extensively studied in metabolic research for over 30 years. Safety profile shows good tolerability in research settings with mild, transient gastrointestinal effects being the most common. Critical limitation: Xenin-25 has NOT completed Phase 3 clinical trials and is not FDA-approved for clinical use. No serious adverse effects have been reported in research studies, but hypoglycemia risk requires careful monitoring when combined with insulin or other glucose-lowering agents. Individual responses to Xenin-25 are generally mild gastrointestinal discomfort, nausea, or headache in the first few days—these typically resolve with continued use. The peptide's glucose-dependent mechanism makes hypoglycemia unlikely when used alone, but additive effects with other agents require medical supervision.

Contraindications

• xMedullary thyroid carcinoma or personal/family history
• xMultiple endocrine neoplasia type 2
• xPregnancy and breastfeeding
• xSevere kidney or liver disease